Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations

Rossi, Giuseppe; Frediani, Sonia; Rossi, Roberta; Rossi, Andrea

doi:10.1186/1471-244x-12-122

Cited by 30 publications

(24 citation statements)

References 131 publications

(166 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, early phase clinical trials suggest that the drug is well tolerated and its PK in man suggests that it is amenable to episodic use. Although LA formulations have improved adherence to drug regimens in a variety of settings including contraception (54), schizophrenia (55), and male hypogonadism (56), clinical trials must be performed to determine whether LA formulations will improve adherence to ARV agents used as PrEP while still demonstrating safety and efficacy. Phase 2 clinical trials to assess the safety and acceptability of GSK744 LA are underway, and should these studies prove successful, then large Phase 3 efficacy studies will soon follow.…”

Section: Discussionmentioning

confidence: 99%

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

et al. 2015

View full text Add to dashboard Cite

GSK1265744 long-acting (GSK744 LA) is a strand-transfer inhibitor of HIV/SIV integrase and was shown to be an effective pre-exposure prophylaxis agent in a low-dose intrarectal SHIV rhesus macaque challenge model. Here, we examined the pharmacokinetics and efficacy of GSK744 LA as PrEP against repeat high-dose intravaginal SHIV challenge in female rhesus macaques treated with Depo-Provera which promotes viral transmission vaginally. When Depo-Provera-treated female rhesus macaques were dosed with 50 mg/kg of GSK744 LA monthly, systemic and tissue drug concentrations were lower than previously observed in male rhesus macaques. GSK744 concentrations were 5-fold lower on average in cervical tissues than rectal tissues. Eight female rhesus macaques were treated with GSK744 LA at week 0, and four female rhesus macaques served as controls. All animals received a high dose challenge of SHIV162P3 at week 1. No infection was detected in GSK744 LA-treated rhesus macaques, whereas viremia was detected 1 to 2 weeks after SHIV challenge in all control animals. The GSK744 LA-treated rhesus macaques were given a second administration of drug at week 4 and further challenged at weeks 5 and 7. GSK744 LA treatment protected 6 of 8 female rhesus macaques against three high-dose SHIV challenges, whereas all control animals became infected after the first challenge (P = 0.0003, log-rank test). These results support further clinical development of GSK744 LA for pre-exposure prophylaxis.

show abstract

Section: Discussionmentioning

confidence: 99%

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

et al. 2015

View full text Add to dashboard Cite

show abstract

“…28,29 Additionally, health-care providers must also take into account the importance of relationships between the person with schizophrenia and their families/significant others when selecting the most appropriate treatment. 30 With a strong therapeutic alliance, the person with schizophrenia, their families and their provider collaborate to identify issues about care that need to be addressed and potential solutions. 28 The goal is to get better and live better, that is, decrease symptoms, increase function, engage in meaningful activity and improve well-being.…”

Section: Person-centred Approachmentioning

confidence: 99%

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia

Stevens

Dawson²,

Zummo

2015

Early Intervention Psych

View full text Add to dashboard Cite

AimResults from clinical trials support the use of oral antipsychotics for treatment of early or first‐episode psychosis in patients with schizophrenia. This paper will review literature on the advantages of early initiation of treatment for schizophrenia and the clinical benefits of early use of long‐acting injectable antipsychotics (LAIs).MethodA comprehensive literature review was conducted to identify published literature on the use of LAIs early in the treatment of schizophrenia.ResultsAlthough there is a higher response rate to initial antipsychotic treatment for a first‐episode of schizophrenia than with subsequent antipsychotic treatment, we have not effectively addressed this issue. Poor adherence to treatment is a primary cause of relapse and rehospitalization in subsequent years and was associated with higher relapse rates resulting in devastating effects and substantial economic burden. The costs of nonadherence were estimated to be $1.48 billion. Thus, a major challenge with the treatment of schizophrenia is changing poor adherence to persistence with antipsychotic therapy. LAIs are known to be at least as effective as oral antipsychotics for treating schizophrenia, and yet are underutilized. Further, LAIs address many of the problems associated with adherence to oral therapy. Recent evidence suggests that LAIs are effective for treating first‐episode psychosis and for early initiation of treatment for schizophrenia.ConclusionAlthough consistent antipsychotic treatment represents a critical part of treatment, a person‐centred approach to treating schizophrenia is essential for all aspects of care, including establishing and maintaining a therapeutic alliance, strengthening shared decision‐making and adherence, and achieving long‐lasting recovery.

show abstract

“…; Rossi et al . ; Schooler ). Because most long‐acting injectable antipsychotic medications are oily suspensions of large volume, they are commonly prescribed for gluteal intramuscular injection (Gillespie & Toner ).…”

Section: Introductionmentioning

confidence: 99%

“…Intramuscular depot injections of long-acting antipsychotic medications are commonly administered to patients with schizophrenia (Berwaerts et al 2015;Chan et al 2015;Manchanda et al 2013;Rossi et al 2012;Schooler 2003). Because most long-acting injectable antipsychotic medications are oily suspensions of large volume, they are commonly prescribed for gluteal intramuscular injection (Gillespie & Toner 2013).…”

Section: Introductionmentioning

confidence: 99%

Comparison of the G and V methods for ventrogluteal site identification: Muscle and subcutaneous fat thicknesses and considerations for successful intramuscular injection

Larkin

Elgellaie

Ashcroft

2017

Int J Mental Health Nurs

View full text Add to dashboard Cite

The ventrogluteal site is increasingly recommended for long-acting antipsychotic intramuscular injections; however, it remains infrequently utilized due to nurses' lack of confidence in site identification. The more recent G (geometric) method of ventrogluteal site identification is less subjective and likely more reliable than the V method for successful intramuscular injection outcomes. Knowledge of muscle and subcutaneous fat thicknesses, and the influence of sex and anthropometry on theoretical injection outcome, is necessary to support evidence-based use of the ventrogluteal site. In the presents study, we compared the V and G methods for injection site subcutaneous fat, muscle, and total tissue thicknesses, and theoretical injection outcome (bone injury, intramuscular or subcutaneous), and determined anthropometric predictors of injection outcome. Subcutaneous fat and muscle thicknesses were measured via ultrasound, bilaterally at V and G method sites (28 males, 32 females). Muscle and total tissue were significantly thicker, and successful intramuscular injection significantly more likely, using the G versus V method (75% versus 57%). Females had significantly thicker subcutaneous fat than males at both sites. Even using the G method, 92% of males but only 59% of females, would have a successful intramuscular injection, with remaining females at risk of bone injury (16%) or subcutaneous injection (25%). The G method site is more reliable for successful intramuscular injection, with less risk of bone injury than the V method site. Appropriate needle-length selection is essential for females with a body mass index (BMI) <23 kg m and weight <60 kg (to avoid bone injury), and BMI >30 kg m and hip >90 cm (to avoid subcutaneous injection).

show abstract

Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations

Cited by 30 publications

References 131 publications

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia

Comparison of the G and V methods for ventrogluteal site identification: Muscle and subcutaneous fat thicknesses and considerations for successful intramuscular injection

Contact Info

Product

Resources

About